InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands
InterCure (NASDAQ: INCR) has announced the strategic acquisition of Botanico Ltd. (ISHI), a premium cannabis technology and brand company. The transaction will be executed in two phases, with InterCure acquiring 100% of ISHI for 4,924,261 ordinary shares, representing approximately 10% of InterCure's fully diluted shares.
The acquisition provides InterCure immediate access to advanced cultivation technologies, exclusive partnerships with leading U.S. cannabis operators including The Flowery, and premium American genetics. The deal comes amid potential cannabis rescheduling from Schedule I to Schedule III by the Trump administration, positioning InterCure to capitalize on evolving U.S. market opportunities.
The transaction is expected to close in Q1 2026, subject to regulatory approvals. ISHI's leadership team, including CEO Omer Layani and COO Dor Hershkovitz, will join InterCure's management. The acquisition is projected to be accretive within the first year.
InterCure (NASDAQ: INCR) ha annunciato l'acquisizione strategica di Botanico Ltd. (ISHI), una società premium di tecnologia e branding nel settore della cannabis. L'operazione sarà eseguita in due fasi, con InterCure che acquisterà il 100% di ISHI per 4.924.261 azioni ordinarie, pari a circa il 10% delle azioni post-diluizione di InterCure.
L'acquisizione offre a InterCure un accesso immediato a tecnologie di coltivazione avanzate, partnership esclusive con importanti operatori statunitensi della cannabis tra cui The Flowery, e genetiche americane di alta gamma. L'accordo arriva in un contesto in cui la cannabis potrebbe essere riclassificata da Schedule I a Schedule III dall'amministrazione Trump, posizionando InterCure per cogliere le opportunità di mercato statunitensi in evoluzione.
L'operazione dovrebbe chiudersi nel Q1 2026, soggetta ad approvazioni regolamentari. Il team dirigenziale di ISHI, tra cui il CEO Omer Layani e il COO Dor Hershkovitz, entrerà nel management di InterCure. Si prevede che l'acquisizione sia accretiva nel primo anno.
InterCure (NASDAQ: INCR) ha anunciado la adquisición estratégica de Botanico Ltd. (ISHI), una empresa premium de tecnología y marca de cannabis. La transacción se realizará en dos fases, con InterCure adquiriendo el 100% de ISHI por 4.924.261 acciones ordinarias, que representa aproximadamente el 10% de las acciones diluidas de InterCure.
La adquisición ofrece a InterCure acceso inmediato a tecnologías de cultivo avanzadas, alianzas exclusivas con importantes operadores de cannabis en EE. UU., incluyendo The Flowery, y genética estadounidense de alto nivel. El acuerdo llega en un momento de posible reclasificación de la cannabis de Schedule I a Schedule III por la administración de Trump, posicionando a InterCure para aprovechar las oportunidades de mercado en evolución en EE. UU.
Se espera que la operación se cierre en el 1T 2026, sujeto a aprobaciones regulatorias. el equipo directivo de ISHI, incluido el CEO Omer Layani y el COO Dor Hershkovitz, se unirán a la dirección de InterCure. Se prevé que la adquisición sea accretiva durante el primer año.
InterCure (NASDAQ: INCR)가 프리미엄 대마초 기술 및 브랜드 기업인 Botanico Ltd. (ISHI)의 전략적 인수를 발표했습니다. 거래는 두 단계로 진행되며, InterCure는 ISHI의 100%를 4,924,261주 보통주에 인수하여 InterCure의 완전 희석 주식의 약 10%를 차지합니다.
인수로 InterCure는 고급 재배 기술, The Flowery를 포함한 미국 주요 대마초 사업자와의 독점 파트너십, 프리미엄 미국 유전자를 즉시 확보하게 됩니다. 거래는 트럼프 행정부의 대마초가 일정 I에서 일정 III로 재분류될 가능성 속에서 미국 시장 기회를 활용할 수 있도록 위치를 잡습니다.
거래는 규제 승인을 조건으로 2026년 1분기에 마무리될 것으로 예상됩니다. ISHI의 CEO Omer Layani와 COO Dor Hershkovitz를 포함한 경영진이 InterCure로 합류합니다. 이 인수는 첫 해 내에 비용 증가 없이 수익에 기여할 것으로 예상됩니다.
InterCure (NASDAQ: INCR) a annoncé l'acquisition stratégique de Botanico Ltd. (ISHI), une société premium de technologies et de marque dans le domaine du cannabis. L'opération se déroulera en deux phases, InterCure acquérant 100% d'ISHI pour 4 924 261 actions ordinaires, soit environ 10% des actions pleinement diluées d'InterCure.
L'acquisition offre à InterCure un accès immédiat à des technologies de culture avancées, des partenariats exclusifs avec des opérateurs cannabis américains de premier plan, dont The Flowery, et des génétiques américaines de premier choix. L'accord survient dans un contexte où la cannabis pourrait être reclassifiée par l'administration Trump du Schedule I au Schedule III, positionnant InterCure pour profiter des opportunités émergentes sur le marché américain.
La transaction devrait être clôturée au 1er trimestre 2026, sous réserve des approbations réglementaires. L'équipe dirigeante d'ISHI, y compris le CEO Omer Layani et le COO Dor Hershkovitz, rejoindra la direction d'InterCure. L'acquisition devrait être créatrice de valeur au cours de la première année.
InterCure (NASDAQ: INCR) hat die strategische Übernahme von Botanico Ltd. (ISHI), einem Premium-Unternehmen für Cannabis-Technologie und -Marken, angekündigt. Die Transaktion wird in zwei Phasen durchgeführt, wobei InterCure 100% von ISHI für 4.924.261 Stammaktien erwirbt, was etwa 10% der vollständig verwässerten Aktien von InterCure entspricht.
Die Akquisition ermöglicht InterCure sofortigen Zugriff auf fortschrittliche Anbautechnologien, exklusive Partnerschaften mit führenden US-Cannabis-Betreibern, darunter The Flowery, und hochwertige US-Genetik. Der Deal erfolgt vor dem Hintergrund einer möglichen Neubewertung von Cannabis von Schedule I zu Schedule III durch die Trump-Regierung und positioniert InterCure, um Marktchancen in den USA besser zu nutzen.
Der Abschluss der Transaktion wird voraussichtlich im 1. Quartal 2026 erfolgen, vorbehaltlich regulatorischer Genehmigungen. Das Führungsteam von ISHI, einschließlich CEO Omer Layani und COO Dor Hershkovitz, wird in das Management von InterCure wechseln. Es wird erwartet, dass die Akquisition im ersten Jahr inkremental wirkt.
InterCure (NASDAQ: INCR) أعلنت عن الاستحواذ الاستراتيجي على Botanico Ltd. (ISHI)، وهي شركة براند وتكنولوجيا القنب premium. ستتم الصفقة على مرحلتين، حيث ستستحوذ InterCure على 100% من ISHI مقابل 4,924,261 سهماً عادياً، ما يمثل نحو 10% من الأسهم المردودة بالكامل لـ InterCure.
يوفر الاستحواذ لـ InterCure وصولاً فورياً إلى تقنيات زراعة متقدمة، وشراكات حصرية مع أبرز مشغلي القنب في الولايات المتحدة بما في ذلك The Flowery، وجينات أمريكية راقية. تأتي الصفقة في ظل احتمال إعادة تصنيف القنب من الجدول I إلى الجدول III من قبل إدارة ترامب، مما يمكّن InterCure من الاستفادة من فرص السوق الأمريكية المتطورة.
من المتوقع إتمام الصفقة في الربع الأول من 2026، رهناً بموافقات تنظيمية. سيضم فريق قيادة ISHI، بمن فيهم الرئيس التنفيذي عمر ليني وCTO دور هيرشكوفيتز، إلى إدارة InterCure. من المتوقع أن تكون الاستحواذ مساهمًا في النمو خلال السنة الأولى.
InterCure（纳斯达克股票代码：INCR）宣布战略性收购Botanico Ltd.（ISHI），这是一家高端大麻科技与品牌公司。交易将分两阶段执行，InterCure将以4,924,261股普通股收购ISHI的全部股权，约占InterCure全部摊薄股本的<对10%>。
此次收购将使InterCure立即获得先进的种植技术、与美国领先大麻运营商（包括The Flowery）的独家伙伴关系，以及高端的美国基因。此交易在特朗普政府将大麻重新列入从I类到III类的潜在重新分类之际，帮助InterCure把握不断发展的美国市场机会。
交易预计在2026年第一季度完成，需获得监管批准。ISHI的领导团队，包括首席执行官Omer Layani和首席运营官Dor Hershkovitz，将加入InterCure管理层。预计该收购在第一年内将实现增厚效应。
- Strategic acquisition provides immediate access to premium U.S. cannabis genetics and advanced cultivation technologies
- Partnership with The Flowery, a leading operator with the largest delivery system in Florida and retail chain in NY
- Transaction expected to be accretive within first year
- Timing aligns with potential U.S. cannabis rescheduling from Schedule I to Schedule III
- All-stock transaction preserves cash resources
- 10% dilution for existing shareholders through share issuance
- Transaction subject to multiple regulatory approvals which could delay closing
- Integration risks with new management team and technology systems
Insights
InterCure's strategic acquisition of ISHI brings premium U.S. cannabis technology and brands, positioning for potential market opportunities if cannabis is rescheduled.
InterCure's acquisition of ISHI represents a strategic milestone in the company's international expansion plans. By acquiring ISHI, InterCure gains access to three critical assets: premium American cannabis genetics, advanced cultivation technologies, and established partnerships with leading U.S. operators like The Flowery.
The deal structure shows careful financial engineering - InterCure is acquiring ISHI in two phases, with the second phase contingent on ISHI achieving positive operating profitability. This performance-based approach reduces immediate financial risk while the
The timing is particularly significant as it coincides with potential cannabis rescheduling in the U.S. If cannabis moves from Schedule I to Schedule III as the Trump administration is reportedly exploring, it would fundamentally alter the regulatory landscape, potentially opening unprecedented access to U.S. markets for international operators like InterCure.
The acquisition delivers immediate operational benefits through ISHI's AI-driven cultivation systems and automated production capabilities. These technological advantages should help InterCure maintain pharmaceutical-grade standards, which are increasingly becoming the global benchmark in medical cannabis.
Most importantly, this move positions InterCure at the intersection of two converging trends: the growing demand for premium, pharmaceutical-grade cannabis products and the potential regulatory shift that could dramatically expand market opportunities. Management expects the acquisition to become accretive within the first year, suggesting confidence in rapid integration and value capture.
Acquisition of leading cannabis company marks major milestone in InterCure’s commercial expansion strategy, bringing access to premium American brands and state-of-the-art cultivation technologies
Transaction comes as Trump administration confirms it is exploring cannabis rescheduling, creating unprecedented potential opportunities for international operators like InterCure
InterCure encouraged by recent regulatory momentum and positioned to capitalize on evolving U.S. cannabis landscape
NEW YORK & HERZLIYA, Israel, Sept. 19, 2025 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced the strategic acquisition of Botanico Ltd., also known as ISHI ("ISHI"), a premium medical cannabis technology and brand company that delivers immediate access to advanced cultivation technologies and established partnerships with leading American cannabis operators. The acquisition comes as the U.S. cannabis market stands at a historic potential inflection point, with the Trump administration reportedly exploring the rescheduling of cannabis from Schedule I to Schedule III1 – a transformative regulatory shift that could unlock unprecedented opportunities for international cannabis companies such as InterCure.
ISHI brings an exclusive partnership with a top tier indoor facility, sophisticated AI-driven cultivation optimization systems, automated production capabilities, and exclusive partnerships with premium U.S. cannabis brands, including established operators like The Flowery, a leading vertically integrated medical cannabis company. The Flowery operates state-of-the-art cultivation and GMP manufacturing facilities alongside the largest delivery system in Florida's medical market. The Flowery also operates the largest retail chain in NY state and has roadmap to continue its aggressive growth in other U.S. markets. Through these partnerships, ISHI has developed exclusive access to highly sought-after American genetics, cult brands and proven cultivation methodologies that have established loyal consumer followings across multiple U.S. markets. The acquisition provides InterCure with immediate access to these award-winning genetics consistently setting U.S. quality standards, advanced operational technologies, and creates substantial competitive advantages as the global medical cannabis market increasingly demands pharmaceutical-grade standards and regulatory frameworks evolve to favor established, compliant operators with proven international capabilities.
Key Transaction Details
- Transaction Structure: Two-phase acquisition of
100% of ISHI (Botanico Ltd.) with50% of the equity acquired at the initial closing in consideration for 2,467,055 InterCure ordinary shares. The remaining50% will be acquired upon the earlier of (i) ISHI achieving positive operating profitability for at least three consecutive months or (ii) 24 months from the initial closing, in consideration for an additional 2,457,206 InterCure ordinary shares. - Total Consideration: 4,924,261 ordinary shares of InterCure, representing approximately
10% of InterCure's outstanding shares on a fully diluted basis - Management Integration: ISHI founders Omer Layani (CEO) and Dor Hershkovitz (COO) join InterCure leadership team
- Employee Transition: All existing ISHI stock options convert to InterCure options, maintaining original vesting schedules
- Expected Closing: Q1 2026, subject to regulatory approvals from The Israeli Medical Cannabis Agency, The Israel Securities Authority, and The Tel Aviv Stock Exchange
- Operational Integration: Immediate transfer of exclusive brand partnerships and technology platform upon closing. The acquisition delivers immediate access to ISHI's premium indoor product supply, brand portfolio, technology, and operational systems that will enhance InterCure's supply chain and distribution operations while supporting expansion into international markets where pharmaceutical-grade standards are becoming the global benchmark.
"This acquisition represents a significant milestone in our global expansion strategy," said Alexander Rabinovich, CEO of InterCure. "By acquiring ISHI, we gain immediate access to some of America's most sought-after cannabis genetics and proven operational technologies at exactly the moment when we are encouraged by the reported recent momentum in the U.S. around potential cannabis rescheduling. This acquisition also represents an additional growth engine for InterCure, and we expect it to become accretive to our business model already within the first year. Today, InterCure is uniquely positioned to capitalize on this historic potential regulatory shift and deliver substantial value to our shareholders."
"Joining InterCure represents the culmination of years building relationships with America's finest cannabis brands," said Omer Layani, CEO of ISHI. "InterCure's global platform and pharmaceutical-grade standards provide the perfect vehicle to scale these partnerships internationally as regulatory tailwinds create unprecedented opportunities for strategic partnerships between U.S. and international operators."
Elad Kohen, Founder and CEO of The Flowery commented: “At The Flowery, our mission is to deliver the highest expressions of Cannabis quality while creating cultural experiences that reflect and elevate the community that built us. Achieving this requires partners who share our uncompromising standards for the plant and embrace a humble, forward-thinking approach. We’ve worked alongside ISHI for years on this project and found deep alignment on the principles that matter most. Today’s announcement strengthens that partnership with greater access and resources, empowering us to expand into new markets the right way-and continue growing our community.”
The transaction remains subject to customary closing conditions and regulatory approvals.
About InterCure (dba Canndoc)
InterCure Ltd. (dba Canndoc) (NASDAQ: INCR) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc Ltd., a wholly owned subsidiary of InterCure, is Israel's largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the fastest growing cannabis global market outside of North America. For more information, visit: https://www.intercure.co
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements may include, but are not limited to, the expected timing for completion of the acquisition of ISHI, the potential for cannabis rescheduling in the U.S., InterCure’s expectation to capitalize on the evolving U.S. cannabis landscape and deliver value to its shareholders. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause InterCure's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the ability of the Company and ISHI to full acquisition closing conditions and obtain regulatory approvals, the Company's success of its global expansion plans, its continued growth, the expected operations, financial results business strategy, competitive strengths, goals and expansion and growth plans, expansion strategy to major markets worldwide, the impact of the COVID-19 pandemic, the impact of the war in Israel and the war in Ukraine and the conditions of the markets generally. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond InterCure's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to: changes in general economic, business and political conditions, changes in applicable laws, the U.S. and Israeli regulatory landscapes and enforcement related to cannabis, changes in public opinion and perception of the cannabis industry, and reliance on the expertise and judgment of our senior management. More detailed information about the risks and uncertainties affecting us is contained under the heading "Risk Factors" included in the Company's most recent Annual Report on Form 20-F and in other filings that we have made and may make with the Securities and Exchange Commission in the future.
Company Contact:
InterCure Investor Relations
ir@intercure.co
+972-77-460-5012
Investor Relations Contact:
Arx Investor Relations
North American & Israeli Equities Desks
InterCure@arxhq.com
1 https://www.cannabisbusinesstimes.com/cannabis-rescheduling/news/15752702/trump-publicly-addresses-cannabis-rescheduling-decision-coming-in-next-few-weeks
FAQ
What is the value of InterCure's acquisition of ISHI?
How will InterCure (NASDAQ: INCR) acquire ISHI?
What strategic benefits does ISHI bring to InterCure?
When will InterCure's acquisition of ISHI close?
How will the ISHI acquisition affect InterCure's financial performance?
